Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

23.87B

Market cap23.87B

Price-Earnings ratio

14.86

Price-Earnings ratio14.86

Dividend yield

—

Dividend yield—

Average volume

1.75M

Average volume1.75M

High today

$117.99

High today$117.99

Low today

$114.74

Low today$114.74

Open price

$115.36

Open price$115.36

Volume

209.39K

Volume209.39K

52 Week high

$132.60

52 Week high$132.60

52 Week low

$84.02

52 Week low$84.02

Stock Snapshot

With a market cap of 23.87B, Incyte(INCY) trades at $117.78. The stock has a price-to-earnings ratio of 14.86.

During the trading session on 2026-10-28, Incyte(INCY) shares reached a daily high of $117.99 and a low of $114.74. At a current price of $117.78, the stock is +2.6% higher than the low and still -0.2% under the high.

Trading activity shows a volume of 209.39K, compared to an average daily volume of 1.75M.

The stock's 52-week range extends from a low of $84.02 to a high of $132.60.

INCY News

Barchart 12h

Incyte reports Q3: everything you need to know ahead of earnings - Barchart.com

...

Simply Wall St 2d

KRAS Cancer Trial Partnership Might Change The Case For Investing In Incyte

Genmab and Incyte recently announced a clinical trial collaboration to test petosemtamab with Incyte’s KRAS G12D inhibitor INCB161734 plus standard chemotherapy...

Simply Wall St 4d

Incyte Enters KRAS G12D Colon Cancer Trial Collaboration With New Combo Focus

Incyte (NasdaqGS: INCY) and Genmab agreed a new clinical trial collaboration to study treatments for KRAS G12D-mutated metastatic colorectal cancer. The partne...

Analyst ratings

52%

of 31 ratings

Buy

41.9%

Hold

51.6%

Sell

6.5%

More INCY News

Zacks 5d

Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint?

Incyte Corporation (INCY Quick QuoteINCY - Free Report) is scheduled to report third-quarter 2026 earnings on Oct. 29, before the opening bell. The Zacks...

Simply Wall St 6d

Incyte Could Be 12% Below Fair Value On ESMO Oncology Data Focus

Incyte (INCY) is drawing attention after announcing plans to showcase new oncology data at the European Society of Medical Oncology Congress 2026 in Madrid, sta...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.